PATENT APPLICATION

DOCKET NO.: 1440.1038-003

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mustapha Abdelouahed and John W. Lawler

Application No.:

10/084,832

Group Art Unit:

1642

Filed:

February 27, 2002

Examiner:

Not assigned

Confirmation No.:

5718

Title:

Diagnostic Assay for Type 2 Heparin-Induced Thrombocytopenia

INFORMATION DISCLOSURE STATEMENT

P.O. B	ant Commissioner for Patents Sox 2327					
Ariing	ton, VA 22202	RECEIVED				
Sir:		NOV 1 9 2002				
This I	nformation Disclosure Statement is submitted: under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)	TECH CENTER 1600/2900				
[X]	under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA stage in an international application; or before the mailing date of a first office action on the merits in a non-CPA, or a Request for Continued Examination).					
[]	under 37 CFR 1.97(c) together with either:					
	[] a Statement under 37 CFR 1.97(e), as checked below, or					
	[] a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)	ECH CENTER 1600/2900				
[]	under 37 CFR 1.97(d) together with:	Z00Z 6 I AON				
	[] a Statement under 37 CFR 1.97(e), as checked below, and					
	[] a \$180.00 fee under 37 CFR 1.17(p), or	BECEINED				
	(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue f	ee)				

[] under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper. (Filed after payment of issue fee)

Stater	<u>nent Ur</u>	<u>ider 37</u>	<u>CFR 1.97(e)</u>			
[]	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or					
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.					
<u>Stater</u>	nent Un	nder 37	CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000)		
[]	Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.					
[X].	Enclosed herewith is form PTO-1449:					
	[X]	Copie	s of the cited references (AA-AC, AL, AR-AZ, and AR2) are enclosed.			
	[]	Applie	Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]			
	[]	The listed references were cited in the enclosed International Search Report in a counterpart foreign application.				
	[]		concise explanation" requirement (non-English references) for reference(s) [37 CFR 1.98(a)(3) is satisfied by:			
		[]	the explanation provided on the attached sheet.			
		[]	the explanation provided in the Specification.			
		[]	submission of the enclosed International Search Report.			
		[]	submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.			
		[]	the enclosed English language abstract.			

[]	Appli	cant requests that the following i	non-published pending applic	cations be considered:			
Examiner Initials	's						
	_	U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []			
		U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []			
	-	U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []			
		Examiner	Date	_			
	[]	A copy of each above-cited app	plication, including the curre	nt claims, is enclosed.			
	[].	A copy of each above-cited application, including the current claims, is enclosed, excepthose entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.					
The E	xamine nces we	r is requested to return a copy of ere considered with the next offic	the above list of pending appete communication.	plications indicating which			
It is re	equested	I that the information disclosed h	erein be made of record in the	nis application.			
Metho	od of pa	yment:					
[]	A cheaccom	ck for the fee noted above is enclopanying Reply. A copy of this S	losed, or the fee has been inc	luded in the check with the			
[]	Please enclos	e charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is sed.					
[X]	R] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0						
		F	Respectfully submitted,				
			IAMILTON, BROOK, SMI	ΓΗ & REYNOLDS, P.C.			
		E	Registration No.: 38,866 Telephone: (978) 341-0036 Facsimile: (978) 341-0136				

Concord, MA 01742-9133 Dated: November 8, 2002